Aimwell Partners Inc. (OTC: AIMN) Enters Final Negotiations to Acquire Healthcare Intellectual Property Independently Valued at $10 Million

Rhea-AI Summary

Aimwell Partners (OTC:AIMN) reported that it has entered final-stage negotiations to acquire a portfolio of healthcare-related intellectual property independently valued at approximately $10 million. The IP is described as aligned with Aimwell's strategy of acquiring and developing technology assets to accelerate innovation across the healthcare ecosystem.

Management believes the proposed acquisition could expand Aimwell's portfolio with assets that may support future commercial applications and long-term shareholder value. However, the company emphasizes that the transaction is still contingent on execution of definitive agreements, satisfactory completion of due diligence, and other customary closing conditions, and notes there is no assurance the deal will be completed on the contemplated terms or at all. Aimwell plans to disclose further details on the IP, its strategic role, and commercialization plans if and when definitive agreements are signed.

News Explained

The deal remains a conditional negotiation: the $10 million valuation is disclosed, but no price, funding, ownership change, or closing is reported.

Aimwell Partners says it has entered final-stage negotiations to acquire healthcare-related intellectual property independently valued at approximately $10 million. Definitive agreements are still being finalized, and the transaction remains subject to due diligence and other closing conditions; the release therefore does not report a completed acquisition, payment, or change to existing ownership.

The $10 million figure is an independent valuation of the portfolio, not a disclosed purchase price or committed funding amount.

The next stated milestone is execution of definitive agreements, after which the company says it intends to provide more details about the assets and its commercialization plans.

News Market Reaction – AIMN

+56.52%

+56.52% Session close to close

In the Jul 13 session, AIMN gained 56.52%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, FL / ACCESS Newswire / July 13, 2026 / Aimwell Partners Inc. (OTCID:AIMN) today announced that it has entered final-stage negotiations to acquire a portfolio of healthcare-related intellectual property that has been independently valued at approximately $10 million.

The intellectual property is expected to complement the Company's long-term strategy of acquiring and developing technology assets that can accelerate innovation across the healthcare ecosystem. While the parties continue to finalize definitive agreements, management believes the proposed acquisition represents a significant opportunity to expand Aimwell's portfolio with assets capable of supporting future commercial applications.

"Healthcare innovation is increasingly being driven by organizations that own and develop meaningful intellectual property," said John Morgan, Chief Executive Officer of Aimwell Partners Inc. "We believe this proposed acquisition aligns with our vision of building a portfolio of strategic healthcare assets that create long-term value for shareholders while supporting innovation throughout the healthcare industry."

The Company cautions that the transaction remains subject to the execution of definitive agreements, satisfactory completion of due diligence, and other customary closing conditions. There can be no assurance that the acquisition will be completed on the terms currently contemplated, or at all.

Upon execution of definitive agreements, Aimwell Partners intends to provide additional details regarding the acquired intellectual property, its strategic significance, and the Company's commercialization plans, as appropriate.

Investor Relations

John Morgan
Aimwell Partners Inc.
Email: corporate@aimwellbio.com

About Aimwell Partners Inc.

Aimwell Partners Inc. (OTC: AIMN) is building the infrastructure for verified healthcare intelligence. Through its technology platforms and strategic acquisitions, the Company is focused on developing data, software, and intellectual property that improve how healthcare professionals, researchers, investors, and organizations evaluate information, make decisions, and create value across the healthcare ecosystem.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the proposed acquisition, the execution of definitive agreements, anticipated closing, the value of the intellectual property, expected strategic benefits, commercialization opportunities, future operations, and shareholder value. These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include, without limitation, the inability to complete negotiations, failure to execute definitive agreements, failure to satisfy closing conditions, adverse due diligence findings, regulatory considerations, financing availability, market conditions, and other risks described in the Company's public filings. Aimwell Partners Inc. undertakes no obligation to update any forward-looking statements except as required by applicable law.

SOURCE: Aimwell Partners

View the original press release on ACCESS Newswire

FAQ

What did Aimwell Partners (OTC:AIMN) announce on July 13, 2026 about a healthcare IP acquisition?

Aimwell Partners announced it is in final-stage negotiations to acquire healthcare-related intellectual property valued at about $10 million. According to Aimwell Partners, the portfolio is expected to align with its strategy of acquiring technology assets that support innovation across the healthcare ecosystem.

How much is the proposed healthcare intellectual property acquisition by Aimwell Partners (AIMN) valued at?

The healthcare-related intellectual property under negotiation is independently valued at approximately $10 million. According to Aimwell Partners, this valuation reflects third-party assessment, and the IP is expected to complement the company’s long-term strategy if a definitive agreement is successfully executed.

Is Aimwell Partners' (OTC:AIMN) $10 million healthcare IP deal finalized?

The healthcare IP deal is not yet finalized. According to Aimwell Partners, completion remains subject to signing definitive agreements, satisfactory due diligence, and customary closing conditions, and there is no assurance the acquisition will be completed on the terms currently contemplated, or at all.

Why is Aimwell Partners (AIMN) pursuing a healthcare intellectual property acquisition?

Aimwell Partners is pursuing the acquisition to expand its portfolio of healthcare-related technology assets. According to Aimwell Partners, management believes the proposed IP could support future commercial applications and aligns with its vision to foster innovation and create long-term shareholder value in healthcare.

What strategic benefits could the proposed healthcare IP bring to Aimwell Partners shareholders (AIMN)?

The proposed IP could broaden Aimwell’s healthcare technology portfolio and support future commercialization efforts. According to Aimwell Partners, management believes this potential acquisition fits its long-term strategy of building strategic assets intended to support innovation and long-term value creation for shareholders, if completed.

What conditions must be met before Aimwell Partners (OTC:AIMN) completes the healthcare IP acquisition?

Completion requires execution of definitive agreements, satisfactory due diligence, and other customary closing conditions. According to Aimwell Partners, until these steps are fulfilled, there can be no assurance that the proposed healthcare intellectual property acquisition will close on the contemplated terms, or at all.